Delving into the Latest Updates on Desmetramadol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

O-DSMT, O-demethyl-tramadol, O-desmethyl-tramadol

+ [4]

Target

NET x μ opioid receptor

Mechanism

NET inhibitors(Norepinephrine transporter inhibitors), μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseCongenital Disorders

Active Indication-

Inactive Indication

Chronic PainDiabetic NeuropathiesDrug Metabolism, Poor, CYP2D6-Related+ [1]

Originator Organization

Syntrix Biosystems, Inc.

Active Organization-

Inactive Organization

Syntrix Biosystems, Inc.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC15H23NO2

InChIKeyUWJUQVWARXYRCG-UYWMCZCJSA-N

CAS Registry80456-81-1

This study evaluates the analgesic effect of Omnitram and tramadol during concurrent administration of paroxetine. Paroxetine administration is expected to diminish the analgesic effect of tramadol, but not Omnitram. Each participant will receive paroxetine before and during treatment with Omnitram, tramadol, and placebo.

Start Date31 Oct 2017

Sponsor / Collaborator

Syntrix Biosystems, Inc.

[+2]

100 Clinical Results associated with Desmetramadol

Login to view more data

100 Translational Medicine associated with Desmetramadol

Login to view more data

100 Patents (Medical) associated with Desmetramadol

Login to view more data

115

Literatures (Medical) associated with Desmetramadol

01 Oct 2024·Saudi Journal of Medicine & Medical Sciences

Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing–Remitting Multiple Sclerosis

Article

Author: Alshamrani, Foziah Jabbar Gossab ; Soltan, Nehad Mahmoud ; Shahid, Rizwana ; Yasawy, Zakia ; Nazish, Saima ; Shariff, Erum ; Alsawad, Rahmah Majed ; Zafar, Azra

AbstractBackground:There is scant data regarding the use of oral disease-modifying treatments (oDMT) in patients with relapsing–remitting multiple sclerosis (PwRRMS) from Saudi Arabia.Objective:This study aimed to identify the response rate to oDMT in PwRRMS compared to interferon (IFN) in terms of achieving no evidence of disease activity-3 (NEDA-3).Methods:This retrospective study was conducted at a tertiary care hospital in Saudi Arabia and included all adult PwRRMS over a 2-year period who were on oDMTs or IFN for <1 year. The achievement of overall NEDA-3 and its components (namely, relapse, disability progression, and focal MRI activity) were assessed for each treatment.Results:A total of 231 patients were included for the analysis of NEDA-3 status, of which 78 (33.8%) were on oDMTs (namely, dimethyl fumarate, teriflunomide, and fingolimod). NEDA-3 status was achieved in 51.3% (OR: 1.86, 95% CI: 1.28–2.71) of patients on oDMTs and in 32% of patients on IFN (OR: 0.72, 95% CI: 0.58–0.89) (P < 0.001). Compared to the IFN group, the oDMT group had significantly lower rates of clinical relapse (P < 0.001), disability progression (P = 0.004), and new focal MRI activity (P = 0.01). Patients on dimethyl-fumarate had higher odds of achieving NEDA-3 (OR: 2.18, 95% CI = 1.09–4.34; P =0.02) compared with those on fingolimod (OR 2.15, 95% CI = 0.70–6.58; P =0.16) and teriflunomide (OR: 1.53, 95% CI = 0.81–2.91; P =0.18).Conclusion:More than half of the patients with relapsing–remitting multiple sclerosis on oral DMTs achieved NEDA-3 status in this study. Significant differences were observed in NEDA-3 status parameters and achievement between patients on oral DMTs and interferon, with the likeliness being highest among patients treated with dimethyl-fumarate.

01 Apr 2024·Medicina Clínica

Análisis retrospectivo de las hipoglucemias inducidas por venlafaxina en pacientes con sobredosis

Article

Author: Elorza Guerrero, Miguel Ángel ; Guiu Marti, Alexandra M ; Socias Crespí, Lorenzo ; Barceló Martín, Bernardino ; Puiguriguer Ferrando, Jordi ; Gomila Muñiz, Isabel

INTRODUCTIONRecent publications relate the presence of hypoglycemia in venlafaxine (VLX) poisoning depending on the dose. Our aim was to analyze the clinical characteristics of patients who presented hypoglycemia induced by VLF overdose.PATIENTS AND METHODSRetrospective study carried out in the Balearic Islands (2020-2023).INCLUSION CRITERIAserum concentrations of VLX + O-desmethyl-venlafaxine (O-VLX)>800 ng/mL. The characteristics of patients with and without hypoglycemia were compared.RESULTSTwenty-one patients were included, 8 (38.1%) with hypoglycemia. No differences were found in the doses referred to in both groups. Peak concentrations of VLX + O-VLX (ng/mL) were 9,783 [4,459-17,976] in patients with hypoglycemia and 1,413 [930-1,719] in patients without hypoglycemia (p<0.0001). The presence of hypoglycemia was associated with: lower age and level of consciousness; and higher frequency of suicide attempts, seizures, mydriasis, tachycardia and serotonin syndrome, invasive respiratory support, fluid therapy and ICU admission (p<0.05).CONCLUSIONSThe detection of hypoglycemia in a VLX overdose case is a readily available marker to suspect the severity of the patient. In any case, serum concentrations when available allow us to confirm intoxication.

01 Dec 2023·International Journal of Biological Macromolecules

Active coatings based on oxidized chitin nanocrystals and silk fibroins for the control of anthracnose in ‘Hass’ avocados

Article

Author: Besoain, Ximena ; Funes, Catalina Ferreira ; Larach, Alejandra ; Van Nhien, Albert Nguyen ; Hadad, Caroline ; Serrano, Daniela Duarte ; Fuentealba, Claudia ; Pedreschi, Romina

Postharvest avocado losses are mainly due to anthracnose disease caused by Colletotrichum gloeosporioides. Chemical fungicides are effective, but their negative effects on health and the environment have led to the search for sustainable alternatives such as biopolymer-based coatings and natural compounds. Therefore, chitin nanocrystals (NCChit) were extracted using a sustainable deep eutectic solvent (DES) and chemically modified into oxidized chitin nanocrystals (O-NCChit) or deacetylated chitin nanocrystals (D-NCChit) to modulate and increase the charge surface density and the dispersibility of the crystals. The modified NCChits were dispersed with silk fibroins (SF), essential oil (EO), melatonin (MT) and/or phenylalanine (Phe) to elaborate active coatings. Antioxidant and antifungal in vitro analyses showed that the O-NCChit/SF-based coating had the best performance. In addition, in vivo tests were carried out through the artificial inoculation of C. gloeosporioides on coated avocados. O-NCChit/SF/MT-based coatings reduced the severity of anthracnose by 45 %, the same effect as the chemical fungicide (Prochloraz®). Moreover, avocado quality parameters during cold storage and the shelf-life period were also evaluated, where nonsignificant differences were observed. Therefore, this study demonstrates the great potential of O-NCChit and SF in combination with active compounds for the control of anthracnose in 'Hass' avocados.

100 Deals associated with Desmetramadol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Desmetramadol	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Pain	Phase 2	US	Syntrix Biosystems, Inc.	15 Nov 2018
Diabetic Neuropathies	Phase 2	US	Syntrix Biosystems, Inc.	15 Nov 2018
Neuralgia	Phase 2	US	Syntrix Biosystems, Inc.	15 Nov 2018
Drug Metabolism, Poor, CYP2D6-Related	Phase 2	US	Syntrix Biosystems, Inc.	31 Oct 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04683926 (CTgov)	Phase 1	Pain	24	Desmetramadol (Desmetramadol 10 mg, Fasted)	xzqvtkalwi(wlfjmyxqmr) = iqnleoyyyh xuykcxbtpd (keawmreccf, ewykcornkf - khfonkyiyw) View more	-	04 Apr 2023
				Desmetramadol (Desmetramadol 20 mg, Fasted)	xzqvtkalwi(wlfjmyxqmr) = ciyvhpkozn xuykcxbtpd (keawmreccf, rctxgmepai - nsjhjtezby) View more